一些功能组化合物的潜力替代了8-曼胺A作为RSK1抑制剂:分子对接和分子动力学模拟
Ala' Omar Hasan Zayed1, Mousa Altarabeen2, Ehab AlShamaileh3
1Department of Chemistry, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia.
Journal of biomolecular structure & dynamics
|February 6, 2024
概括
海洋化物被探索为针对RSK1.1的新型抗癌剂. 化合物A5和相关衍生品显示出作为RSK1抑制剂的显著潜力,需要进一步研究癌症治疗.
科学领域:
- 药用化学 医学化学
- 计算机化药物设计技术
- 癌症研究 癌症研究
背景情况:
- 癌症仍然是一个重要的全球健康挑战,需要新的治疗策略.
- 海洋类化合物,如Manzamine A衍生物,显示出作为阻断核糖体S6激酶 (RSK) 抑制剂对抗癌细胞入侵的希望.
- 修改曼扎明A在8位,特别是与基组,增强其生物活性.
研究的目的:
- 设计和评估新型功能化的8-Manzamine A衍生物作为RSK1.1的潜在抑制剂.
- 以计算方式评估这些化合物与RSK1 N-终端激酶域的结合亲和力和动态相互作用.
主要方法:
- 使用Glide模块进行分子对接,以预测设计联体 (A1-A21) 与RSK1 (PDB ID: 2Z7Q) 的结合模式.
- 使用MM-GBSA进行具有约束力的能源计算.
- 用德斯蒙德和温和元动力学 (WT-MetaD) 进行分子动力学 (MD) 模拟,以探索复杂的稳定性和能量学.
主要成果:
- 化合物A5获得了最高的G评分 (-7.01),表现优于8-氧曼胺A (-6.08).
- 与原始化合物相比,A6,A10,A12,A17,A11,A4和A13化合物显示出增强的RSK1抑制活性.
- 关键的RSK1残留物 (LEU68,VAL76,LEU141,PHE143,LEU144,PHE150,ASP148,GLU191,LEU194) 被确定为关键的联体结合.
- MD和WT-MetaD模拟证实了A5/RSK1复合物的稳定性,并确定了有利的结合形状.
结论:
- 设计的8-曼胺A衍生物,特别是A5,A6,A10,A12,A17,A11,A4和A13,显示出作为RSK1抑制剂的显著潜力.
- 这些化合物表现出有希望的结合亲和性和动态相互作用,表明它们对进一步抗癌药物开发的可行性.
- 计算方法有效地预测和验证了这些新型海洋类衍生物的抑制潜力.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
10:07High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
Published on: January 27, 2013
15.1K
相关概念视频
Structure-Activity Relationships and Drug Design
721
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
721
Nucleophilic Aromatic Substitution of Aryldiazonium Salts: Aromatic SN1
2.1K
Treating arylamines with nitrous acid gives aryldiazonium salts that are effective substrates in nucleophilic aromatic substitution reactions. The diazonio group in these salts can be easily displaced by different nucleophiles, yielding a wide variety of substituted benzenes. The leaving group departs as nitrogen gas, and this easy elimination is the driving force for the substitution reaction.
In the Sandmeyer reaction, for example, the diazonio group is replaced by a chloro, bromo,...
In the Sandmeyer reaction, for example, the diazonio group is replaced by a chloro, bromo,...
2.1K
Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K
